CENTESSA PHARMACEUTICALS PLC CNTA 深 沪
等待开盘 09-17 09:30:00 美东时间
21.33
-0.690
-3.13%
华盛通- 最 高22.2198
- 今 开22.06
- 成交量 115.89万股
- 最 低 20.94
- 昨 收 22.02
- 总市值 28.58亿
- 52周最高 23.24
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 9.60
- 委 比 -78.22%
- 总股本 1.34亿
- 历史最高 26.90
- 量 比 0.57
- 振 幅 5.81%
- 历史最低 2.885
- 每 手 1
- 风险率 2.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
09-12 17:27
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Centessa Pharmaceuticals plc announced that its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. A fireside chat is scheduled for September 9th at 4:50 PM ET. The event will be available via live audio webcast and archived recording on the company's investor relations website. Centessa focuses on discovering and developing transformational medicines for patients, particularly through its...
09-03 11:00
Centessa rated Outperform at Oppenheimer on ORX750 potential
Centessa Pharmaceuticals (NASDAQ:CNTA) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset, ORX750, an orexin-2 receptor agonist. This upgrade comes a...
08-30 02:53
Centessa Pharmaceuticals Advances Orexin Agonist Pipeline
Centessa Pharmaceuticals Plc ( ($CNTA) ) has released its Q2 earnings. Here is ...
08-13 12:22
Centessa Pharmaceuticals Q2 EPS $(0.38) Misses $(0.34) Estimate
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.34) by 11.44 percent. This is a 5 percent increase over losses of $(0.40) per share
08-12 19:16
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Centessa Pharmaceuticals reported progress in advancing its best-in-class orexin receptor 2 (OX2R) agonist pipeline, including the Phase 2a CRYSTAL-1 study of ORX750 for narcolepsy and idiopathic hypersomnia, and the Phase 1 trial of ORX142 for neurological disorders. ORX489 is in IND-enabling studies for neuropsychiatric conditions. The company highlighted its strong cash position and expanded pipeline, aiming to redefine treatment standards for...
08-12 11:00
美股大行评级 | 潜在涨幅57.1%！Macquarie上调Marathon Digital目标价至26美元，维持"跑赢大市"评级
今日重点评级关注：Macquarie：维持Marathon Digital"跑赢大市"评级，目标价从19美元升至26美元；巴克莱：维持Universal Health Services"超配"评级，目标价从257美元升至259美元
07-31 09:05
Chardan Capital Maintains Buy on Centessa Pharmaceuticals, Maintains $30 Price Target
Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.
07-31 06:05
Truist Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30
Truist Securities analyst Danielle Brill initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $30.
07-21 19:54
Nxera Pharma Secures $4.8 Million Milestone Payment from Centessa
Sosei Group ( ($JP:4565) ) just unveiled an update. Nxera Pharma announced it w...
07-04 07:52
